TrialThe Journal of international medical research2024

Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).

Xiangyan Ruan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.